EGFR and colorectal carcinoma: For instance, the epidermal growth factor receptor (EGFR) neutralizing monoclonal antibodies cetuximab (an immunoglobulin G1 (IgG1) mouse–human chimeric monoclonal antibody) and panitumumab (a recombinant, fully humanized, IgG2 monoclonal anti-EGFR antibody) are both approved by the Food and Drug Administration (FDA) as standard of care for patients with CRC [3,4,5].